Pacira Pharmaceuticals, Inc. Reports 2015 Financial Results
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 6/22/2026
- S&P 500, Nasdaq fall, dragged by Alphabet and megacap tech; focus on Iran
- Oil settles down more 3% after US-Iran talks signal easing supply risks
- Micron surges 5.5% on blockbuster Anthropic AI deal ahead of earnings
- Alan Greenspan, influential former Federal Reserve chair, dies at 100
- Buy gold stocks as valuations are cheap amid macro tension: BofA
- CoreWeave trains DeepSeek-V3 in two minutes in MLPerf benchmark
- Needham Starts NeoVolta (NEOV) at Buy
- Li Auto Inc. (LI) Breaks Ground on Chips R&D and Production Base
- Spain's ex-transport minister sentenced to 24 years for corruption
- Exclusive-China robot-hand-building unicorn Linkerbot targets $6 billion valuation
Pacira Pharma (PCRX) Misses Q4 EPS by 5c, Sales Beat
February 25, 2016 7:34 AM ESTPacira Pharma (NASDAQ: PCRX) reported Q4 EPS of $0.22, $0.05 worse than the analyst estimate of $0.27. Revenue for the quarter came in at $69.3 million versus the consensus estimate of $68.4 million.
We finished 2015 with a solid performance in spite of the challenges we faced this past... More
